




參考文獻:
[1].Xie J, Xia L, Xiang W, et al. Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1[J]. Proceedings of the National Academy of Sciences, 2020.
[2].ARRIETA O, BARRóN F, PADILLA M-á S et al.Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With TyrosineKinase Inhibitors Alone in Patients With Epidermal Growth FactorReceptor–Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial[J].JAMA oncology, 2019: e192553.
[3].Chen H, Yao W, Chu Q, et al. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes[J]. Cancer Letters, 2015, 369(1): 97-102.
[4].Soria J C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer[J]. New England Journal of Medicine, 2018, 378(2): 113-125.
[5].Binnewies M, Roberts E W, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nature medicine, 2018, 24(5): 541-550.
[6].Yanik E L, Kaunitz G J, Cottrell T R, et al. Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy[J]. JAMA oncology, 2017, 3(7): 974-978.
上下滑動(dòng)查看更多圖片
溫馨提示:本文涉及醫療內容為普遍適用性建議,僅供學(xué)習和參考,最終意見(jiàn)以臨床醫師診斷為準
聯(lián)系客服